{"nctId":"NCT00168818","briefTitle":"Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery","startDateStruct":{"date":"2004-11"},"conditions":["Thromboembolism","Arthroplasty, Replacement, Hip"],"count":3494,"armGroups":[{"label":"dabigatran etexilate 75 mg","type":"EXPERIMENTAL","interventionNames":["Drug: dabigatran etexilate"]},{"label":"dabigatran etexilate 110 mg","type":"EXPERIMENTAL","interventionNames":["Drug: dabigatran etexilate"]},{"label":"enoxaparin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: enoxaparin"]}],"interventions":[{"name":"dabigatran etexilate","otherNames":[]},{"name":"dabigatran etexilate","otherNames":[]},{"name":"enoxaparin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\nInclusion criteria (selected):\n\n* Patients (18 years or older) scheduled to undergo a primary, unilateral, elective total hip replacement\n* Written Informed Consent\n\nExclusion criteria\n\nExclusion criteria (selected):\n\n* Patients with an excessive risk of bleeding, for example because of history of bleeding diathesis major surgery or trauma within the last 3 months history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, AV malformation or aneurysm clinically relevant bleeding or gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days prior to joint replacement surgery or anticipated need during the study treatment period thrombocytopenia.\n* Active malignant disease or current cytostatic treatment\n* Known severe renal insufficiency\n* Liver disease expected to have any potential impact on survival, or elevated AST or ALT \\> 2x upper limit of normal\n* Recent unstable cardiovascular disease or history of myocardial infarction within the last 3 months\n* Pre-menopausal women who are pregnant or nursing, or are of child-bearing potential and are not practising or do not plan to continue practising acceptable methods of birth control\n* Allergy to radio opaque contrast media or iodine, heparins (incl. heparin induced thrombocytopenia) or dabigatran\n* Contraindications to enoxaparin\n* Participation in a clinical trial during the last 30 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period","description":"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).\n\nAll of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period","description":"Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Proximal Deep Vein Thrombosis During Treatment Period","description":"Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Deep Vein Thrombosis During Treatment Period","description":"Total Deep Vein Thrombosis as adjudicated by the VTE events committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptomatic Deep Vein Thrombosis During Treatment Period","description":"Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Pulmonary Embolism During Treatment Period","description":"Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Death During Treatment Period","description":"All cause death, as adjudicated by the VTE events committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period","description":"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period","description":"Major bleeding events were defined as\n\n* fatal\n* clinically overt associated with loss of haemoglobin \\>=20g/L in excess of what was expected\n* clinically overt leading to the transfusion of \\>=2 units packed cells or whole blood in excess of what was expected\n* symptomatic retroperitoneal, intracranial, intraocular or intraspinal\n* requiring treatment cessation\n* leading to re-operation\n\nClinically-relevant was defined as\n\n* spontaneous skin hematoma greater than or equal to 25 cm²\n* wound hematoma greater than or equal to 100 cm²\n* spontaneous nose bleed lasting longer than 5 min\n* macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention\n* spontaneous rectal bleeding (more than a spot on toilet paper)\n* gingival bleeding lasting longer than 5 min\n* any other bleeding event considered clinically relevant by the investigator\n\nMinor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1005","spread":null},{"groupId":"OG001","value":"1021","spread":null},{"groupId":"OG002","value":"1022","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Transfusion","description":"Blood transfusion for treated and operated patients on Day of surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"517","spread":null},{"groupId":"OG001","value":"531","spread":null},{"groupId":"OG002","value":"542","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"266","spread":null},{"groupId":"OG002","value":"286","spread":null}]}]}]},{"type":"SECONDARY","title":"Volume of Blood Loss","description":"Volume of blood loss for treated and operated patients during surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457","spread":"304"},{"groupId":"OG001","value":"435","spread":"271"},{"groupId":"OG002","value":"463","spread":"291"}]}]}]},{"type":"SECONDARY","title":"Laboratory Analyses","description":"Frequency of patients with possible clinically significant abnormalities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":89,"n":1146},"commonTop":["Nausea","Vomiting","Constipation","Pyrexia","Insomnia"]}}}